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ABSTRACT
Introduction: The aim of this article is to
discuss methods used to analyze health-related
quality of life (HRQoL) data from randomized
controlled trials (RCTs) for decision analytic
models. The analysis presented in this paper was
used to provide HRQoL data for the ivabradine
health technology assessment (HTA)
submission in chronic heart failure.
Methods: We have used a large, longitudinal
EuroQol five-dimension questionnaire (EQ-5D)
dataset from the Systolic Heart Failure
Treatment with the If Inhibitor Ivabradine
Trial (SHIFT) (clinicaltrials.gov: NCT02441218)
to illustrate issues and methods. HRQoL weights
(utility values) were estimated from a mixed
regression model developed using SHIFT EQ-5D
data (n = 5313 patients). The regression model
was used to predict HRQoL outcomes according
to treatment, patient characteristics, and key
clinical outcomes for patients with a heart rate
C75 bpm.
Results: Ivabradine was associated with an
HRQoL weight gain of 0.01. HRQoL weights
differed according to New York Heart
Association (NYHA) class (NYHA I–IV, no
hospitalization: standard care 0.82–0.46;
ivabradine 0.84–0.47). A reduction in HRQoL
weight was associated with hospitalizations
within 30 days of an HRQoL assessment visit,
with this reduction varying by NYHA class
[-0.07 (NYHA I) to -0.21 (NYHA IV)].
Conclusion: The mixed model explained
variation in EQ-5D data according to key
clinical outcomes and patient characteristics,
providing essential information for long-term
predictions of patient HRQoL in the
cost-effectiveness model. This model was also
used to estimate the loss in HRQoL associated
with hospitalizations. In SHIFT many
hospitalizations did not occur close to EQ-5D
visits; hence, any temporary changes in HRQoL
associated with such events would not be
captured fully in observed RCT evidence, but
could be predicted in our cost-effectiveness
analysis using the mixed model. Given the
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large reduction in hospitalizations associated
with ivabradine this was an important feature of
the analysis.
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INTRODUCTION
The reimbursement of new pharmaceutical
products is increasingly dependent on the
results of cost-effectiveness analyses.
Economic evaluations developed for health
technology assessment (HTA) bodies such as
the National Institute for Health and Care
Excellence (NICE) typically adopt
quality-adjusted survival as the relevant
outcome measure [1]. Quality-adjusted
survival uses health-related quality of life
(HRQoL) weights (utility values) to adjust
survival time to reflect the outcome of the
population under assessment. HRQoL weights
typically represent patients’ quality of life on a
scale where 0 represents death and 1 represents
full health, although negative values are also
feasible [2, 3]. In the event that randomized
controlled trial (RCT) data is used to inform a
decision analytic model, the appropriate
analysis of HRQoL data from the RCT is
crucial for reliable policy decisions.
Longitudinal HRQoL data from RCTs
presents challenges to analysts. The
distribution of EuroQol five-dimension
questionnaire (EQ-5D) HRQoL data is typically
left skewed and kurtotic. In addition, there are
further issues which are specific to the analysis
of such data for cost-effectiveness analyses.
Firstly, in chronic conditions such as heart
failure (HF), cost-effectiveness analyses consider
the impact of each intervention over the
modelled populations’ lifetime, but RCTs
usually provide only short-term data.
Long-term HRQoL outcomes consequently
need to be estimated either from an external
data source or predicted (extrapolated) from
observed RCT evidence. Appropriate
extrapolation requires that the variation in
HRQoL observed between patients is
adequately explained.
Secondly, in order to predict clinical
outcomes over the long term, a
cost-effectiveness analysis typically captures
key clinical outcomes including disease
progression and resource use data such as
hospitalizations. The HRQoL impact of these
outcomes must also, therefore, be established in
order to suitably populate a decision analytic
model.
Thirdly, clinical outcomes such as
hospitalization or disease progression may
result in fluctuations in patient HRQoL over
time. Temporary changes in HRQoL that do not
occur within sufficient proximity to data
collection points will not be reflected in
observed RCT data. This issue is exacerbated in
studies which have long periods between
HRQoL assessments and can result in diluted
or imprecise measures of the difference between
treatments.
Fourthly, longitudinal HRQoL data are
collected from the same individual at repeated
intervals over the study period. Measurements
from the same individual are much more likely
to be correlated than measurements from
different individuals and this correlation must
be taken into account to avoid misrepresenting
estimates [1].
Fifthly, HRQoL data are often collected in a
substudy and, whilst patients may be
randomized to treatment, participants may
not be randomized to the substudy itself (e.g.,
they may be selected from certain study centers
or countries). If there are imbalances in patient
characteristics associated with HRQoL
outcomes in substudy patients this may bias
(i.e., confound) estimates of the treatment
effect [4].
Finally, HRQoL data are often incomplete.
Patients are less likely to complete HRQoL
questionnaires as their condition deteriorates
and time progresses (informative censoring). In
general this could result in imprecise HRQoL
estimates in later trial time periods for both
treatment groups, but it could equally result in
differential bias between therapies [5].
The key objective of this article is to discuss
methods to analyze HRQoL data from RCTs to
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parameterize decision analytic models using an
example based on an analysis of EQ-5D data
from the Systolic HF Treatment with the If
Inhibitor Ivabradine Trial (SHIFT) RCT
(clinicaltrials.gov: NCT02441218). The HRQoL
regression equation presented in this paper was
used to provide HRQoL weights (utility values)
for the cost-effectiveness analysis developed for
the ivabradine NICE HTA submission in chronic
heart failure; the full results of the
cost-effectiveness analysis and associated
clinical data are reported elsewhere [4, 5].
METHODS
SHIFT Trial
Heart failure is a chronic condition which can
result in substantial morbidity, reduced HRQoL,
and premature death [6, 7]. SHIFT was a
multicenter RCT conducted in 6505 HF
patients with New York Heart Association
(NYHA) class II, III, or IV HF, in sinus rhythm,
and with left ventricular ejection fraction
(LVEF) B35% and baseline resting heart rate
C70 bpm. SHIFT demonstrated that ivabradine,
a heart rate lowering therapy, in combination
with standard therapy, including beta-blockade,
was associated with a significant reduction in
cardiovascular (CV) death or hospitalization for
worsening HF (hazard ratio 0.82; 95%
confidence interval 0.75, 0.90, p\0.0001) and
improved patient HRQoL [8]. SHIFT was a
robust, well-conducted study and provides one
of the largest samples of EQ-5D HRQoL data
from an RCT in HF patients.
HRQoL Data Collection in SHIFT
SHIFT EQ-5D HRQoL data were collected in a
substudy at baseline, 4 months, and annually
until study close providing up to five HRQoL
assessments for each patient over the observed
trial period (median follow-up 22 months) [9].
The EQ-5D is a generic instrument designed to
capture patient-reported outcomes across five
health domains (self-care, mobility, usual
activities, pain/discomfort, anxiety/depression)
[2]. HRQoL weights (utility values) may be
derived from the EQ-5D using country-specific
values for different health profiles. All patients
randomized in SHIFT were included in the
EQ-5D substudy (n = 5313/6505 patients)
providing a validated EQ-5D instrument was
available for the country of interest (i.e., an
approved country-specific EQ-5D
questionnaire). The SHIFT cost-effectiveness
analysis was undertaken from a UK National
Health Service and Personal and Social Services
(PSS) perspective [1]; hence in our analysis,
HRQoL weights values were based on EQ-5D
index scores using UK population
preference-weights [10].
Analysis of HRQoL Data
A de novo analysis of SHIFT HRQoL data was
required to provide suitable parameter estimates
for the SHIFT cost-effectiveness analysis. There
are a number of approaches that can be used to
analyze longitudinal HRQoL data for a
cost-effectiveness analysis from RCTs such as
SHIFT. Simple summary measures may be used
to estimate the effect of treatment on HRQoL
outcomes directly, e.g., based on the mean
difference in HRQoL between treatments at
one or more intervals over the trial period.
Summary estimates from observed data,
however, may not capture the full impact of
clinical events that result in temporary
fluctuations in HRQoL, such as
hospitalizations, as some such events occur
outside of data collection. Summary estimates
equally do not take into account correlation
between repeated observations from the same
individual. Measurements from the same
individual are much more likely to be
correlated than measurements from different
individuals and it is important to take into
account such correlation when analyzing data
with repeated measures to avoid
misrepresenting uncertainty in estimates and
drawing incorrect inferences. Furthermore,
from an economic modelling perspective,
simple summary measures do not provide
estimates over a sufficient time horizon nor
provide adequate explanation of the variation
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in HRQoL to populate a cost-effectiveness
analysis [11].
In addition to summary measures, a variety
of regression approaches can be applied to
analyze longitudinal HRQoL data. These
include general linear models (GLM) and
generalized estimating equations (GEE).
A GLM framework attempts to explain
variation in HRQoL according to known
factors including, e.g., treatment allocation,
patient baseline characteristics, and key
clinical outcomes. Whilst this approach can be
used to explain potential variation in HRQoL
outcomes, it is also not designed to explicitly
take into account the longitudinal structure of
the data (repeated observations for individuals
over time) [12].
A GEE framework (also known as marginal or
population averaged model) is an extension to
GLM which takes into account the correlation
associated with repeated sampling from the
same individual by adjusting standard errors
using an imposed (predefined) correlation
structure [13].
Multilevel modelling techniques, in
particular mixed models (also known as
variance components modelling, hierarchical
modelling, or panel data modelling) can also be
used to analyze longitudinal HRQoL. There are
two ways of measuring effects in multilevel
modelling: fixed effects and random effects. A
fixed effects model assumes that the intercept
for each patient is fixed. This substantially
increases the number of parameters in the
model and consequently a fixed effects model
can be inefficient in terms of degrees of
freedom; furthermore time-invariant variables
will be dropped because of the correlation
between regressors and unobserved individual
heterogeneity. A fixed effects model is likely to
be preferable if the purpose of the model is only
to provide predictions on the sample of data
itself [12–14].
A random effects model is designed to
estimate subject-specific effects and, hence,
provides distilled estimates of the specified
covariates (i.e., a fixed component of the
model), plus estimates of random variation
according to clusters (i.e., a random
component of the model). For longitudinal
HRQoL data the individual patient represents
the cluster in which multiple observations over
time are nested. A mixed model may include
fixed or random coefficients for time-varying
variables. A mixed model which includes fixed
coefficients is termed a random intercept
model, whilst a model which includes random
coefficients for any time varying variable is a
random coefficient model. Mixed models
provide a flexible framework compared to
GLM or GEE approaches; however, these
models are not as parsimonious and require a
large sample size to generate reliable results
[12–14].
Statistical Methods
We evaluated HRQoL outcomes based on SHIFT
EQ-5D data for the SHIFT cost-effectiveness
analysis. We considered estimates of the
intraclass correlation (ICC) to determine
whether a multilevel model would be
preferable to a GLM. The ICC estimates the
proportion of variance in a regression model
due to clustering and is calculated as the ratio of
between cluster variance and the total variance.
Intraclass correlation takes values from 0 to 1; if
there is little or no difference between cluster
means the ICC will be close to zero (i.e., simple
linear regression model may be appropriate),
whilst a value of 0.5 would be considered a large
ICC [15], suggesting a multilevel model would
be preferred.
Patient characteristics considered for
selection in the regression model were based
on the clinical study protocol, a previous
regression equation in HF [10], and clinical
advice and included baseline sociodemographic
and clinical characteristics [age, sex, NYHA
class, HF duration, LVEF, smoking status,
alcohol use, diabetes, race, body mass index
(BMI)], baseline use of HF medications
[beta-blockers, angiotensin-converting enzyme
inhibitors, aldosterone antagonists, loop
diuretics (dose/kg/day), angiotensin II receptor
antagonists, cardiac glycosides, allopurinol],
baseline use of other cardiac therapies (cardiac
resynchronization, implantable cardiac
device, conventional bradycardia-indicated
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pacemaker), medical history, i.e., prior CV
event (myocardial infarction, stroke, coronary
artery disease, atrial fibrillation, renal disease,
hypertension), and biological characteristics
(serum sodium, potassium, creatinine
clearance, cholesterol systolic blood pressure).
Two time-varying variables were used to capture
key clinical outcomes: hospitalization within a
2-month interval (hospitalizations were flagged
if they occurred ±30 days from EQ-5D visit date;
a 60-day window) and NYHA class. Each
hospitalization was assumed to be associated
with a change in HRQoL weights over a
2-month period. It is assumed that patients’
HRQoL would be affected up to 30 days before
an admission (i.e., due to onset of illness) and
up to 30 days after an admission (i.e., recovery).
We recognize that this may or may not
represent the exact duration of a
hospitalization’s impact on a patient’s HRQoL;
acute admissions may occur suddenly and
recovery may be shorter or longer than the
window considered. This time interval was
chosen on the basis of clinical advice and
according to practical constraints (number of
observations available for analysis and a time
period which would be consistent with the
model cycle length and viable for the
cost-effectiveness analysis).
Ivabradine exhibited greater efficacy in
patients with higher baseline heart rates in
SHIFT [15]; hence, the European license for
ivabradine was granted for a subgroup of the
trial population—patients with a baseline heart
rate C75 bpm (SHIFT n = 4154/6505 patients).
In our analysis the HRQoL regression model was
developed using data from the entire SHIFT
substudy cohort (n = 5313 patients). The
difference in outcomes for ivabradine
associated with baseline heart rate, identified
in previous clinical analyses [8, 15], is captured
in the HRQoL regression equation using a
treatment interaction term
(treatment 9 baseline heart rate). In order to
match the population reflected in the license
indication, the HRQoL estimates used in the
cost-effectiveness analysis and reported in this
manuscript reflect estimates for patients with a
baseline heart rate C75 bpm (predicted from our
regression equation) [5].
An initial set of variables were identified
using backwards stepwise elimination and cross
validated using forwards stepwise selection. The
regression model was fitted with and without
the variable of interest, the direction and
magnitude of effect of other variables was
reviewed, and a likelihood ratio test
undertaken to test the significance of the
nested model. The variables included in the
regression model were those variables that
demonstrated evidence of an important
association with HRQoL outcomes based on
magnitude and significance of effect (p\0.05).
The correlation matrix for the initial regression
model was reviewed and those variables which
appeared strongly correlated were further
analyzed for evidence of collinearity. All
variables included in the final HRQoL
regression model were reviewed by a clinical
expert to ascertain whether any spurious or
unexpected results had been obtained and
whether the direction and magnitude of effect
for included variables was consistent with
clinical expectations based on a knowledge of
the published literature and clinical practice.
Data were analyzed using the Stata xtmixed
command in Stata Statistical Software: Release
11 (College Station, Texas, United States,
StataCorp LP 2009 [16]).
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
EQ-5D data were collected for 5313 individual
patients (2648 patients ivabradine, 2665
patients placebo) for up to five assessments
(median follow-up in SHIFT was 22 months).
EQ-5D data were available for 5313 patients at
baseline, 5164 patients at 4 months, 4809
patients at 12 months, 2555 patients at
24 months, and 33 patients at 36 months. The
reason for missing questionnaires included
death, withdrawal, non-attendance for a given
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EQ-5D visit, non-completion of the
questionnaire, and censoring [9].
The SHIFT EQ-5D HRQoL weights data were
found to be left-skewed (-1.25 versus 0 for a
symmetric distribution) and kurtotic (5.67
compared to 3.00 for a normal distribution)
with a mean slightly less than the median
(Fig. 1). One way to analyze data with these
characteristics would be to transform the data
to reduce skewness and non-normality of the
data; however, problems can arise when
predictions from the regression model must be
retransformed back to the original scale. In our
analyses we did not transform HRQoL data—
whilst a normal probability plot demonstrated
some evidence of skewness, most data points lay
over the range between 0.5 and 0.9 and the
non-normality of the data was not considered
extreme, see Fig. 1. Furthermore, upon
investigating the model residuals, whilst
HRQoL weights values were skewed, the
residuals appeared approximately normally
distributed.
Patient characteristics appeared well
balanced between treatment groups in the
EQ-5D substudy and were comparable to the
baseline characteristics represented in the full
SHIFT trial population, suggesting the substudy
was a representative sample and there was no
evidence to suggest confounding by known risk
factors (Table 1).
A multilevel model was employed in
preference to a GLM because there was
evidence of intraclass correlation across
clusters (ICC = 0.46). A log-likelihood ratio
test comparing a standard linear model with
linear mixed model was also statistically
significant (p\0.001), also suggesting a
multilevel regression model was preferable to a
GLM. A random effects model was selected in
preference to a fixed effects model since the
cost-effectiveness analysis was designed to
provide distilled population level estimates
and for a specific subgroup population
(patients with a baseline heart rate C75 bpm)
rather than the entire SHIFT sample;
furthermore, a random effects model is more
efficient in terms of parameter estimation
[12–14]. For the final regression equation, we
consequently chose to analyze SHIFT HRQoL
data using a random effects (mixed model). This
model was designed to predict EQ-5D HRQoL
weights values according to treatment
allocation, baseline patient characteristics, and
key clinical outcomes. It is acknowledged that
for continuous outcomes a random intercept
model is comparable to a GEE (marginal model)
with a uniform correlation covariance structure.
Whilst, in our example, a marginal model may
have been sufficient, a marginal model makes a
stronger assumption with regards to missing
data compared to a mixed model. A marginal
model assumes that missing data is missing
completely at random and there is no
relationship at all between the propensity for
missing data and any value in the dataset,
Fig. 1 SHIFT EQ-5D HRQoL data. EQ-5D EuroQol
five-dimension questionnaire. Normal probability plot
depicts expected EQ-5D values based on the standard
normal distribution versus observed EQ-5D values.
Histogram depicts observed frequency for each EQ-5D score
(all observations) with kernel density smoother overlaid
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Table 1 Baseline characteristics
Description Standard care
n5 2665 patients
Ivabradine
n5 2648 patients
Mean/freq SE/% Mean/freq SE/%
Demographics
Age (years) 60.30 0.22 60.63 0.22
BMI (m2/kg) 28.14 28.13
Female 599 22.5% 627 23.7%
Vital signs
Heart rate (bpm) 79.98 0.19 79.45
Systolic blood pressure (mmHg) 121.78 122.25
LVEF category
\26% 622 23.3% 633 23.9%
C26%,\30% 460 17.3% 419 15.8%
C30%,\33% 742 27.8% 705 26.6%
C33% 841 31.6% 891 33.7%
NYHA class
II 1254 47.1% 1264 47.7%
III 1361 51.1% 1346 50.8%
IV 50 1.9% 38 1.4%
Medical history
HF duration
\0.6 years 628 23.6% 625 23.6%
C0.6,\2 years 690 25.9% 676 25.5%
C2,\4.8 years 665 25.0% 696 26.3%
C4.8 years 682 25.6% 651 24.6%
Primary cause of heart failure
Non-ischemic 809 30.4% 795 30.0%
Ischemic 1856 69.6% 1853 70.0%
MI 1564 58.7% 1538 58.1%
Hypertension 1791 67.2% 1782 67.3%
Diabetes 820 30.8% 781 29.5%
Prior stroke 240 9.0% 199 7.5%
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whilst a mixed model assumes that data are
missing at random.
The results of the mixed model suggest that
patient’s HRQoL reduced substantially with
increasing NYHA class (indicative of more
severe HF) or hospitalization. Other risk factors
associated with important differences in HRQoL
included treatment, BMI, LVEF, HF duration,
prior stroke, ischemia, and the use of other
medications including loop diuretics and
allopurinol, possibly indicating that patients
using these medications may have been in
generally poorer health. Cross tabulation of
loop diuretic use and baseline NYHA class
indicated that 1925/2518 (76.4%) of patients
classed as NYHA I used loop diuretics compared
with 81/88 (92.0%) of patients classed as NYHA
IV; only 6.1% (331/5313) of all patients
included in the SHIFT HRQoL substudy
population used allopurinol; hence, usage
patterns for this drug were more difficult to
determine. Female and older patients also
appeared to have lower HRQoL, consistent
with previously published studies (see Tables 2,
3) [10]. Baseline heart rate was inversely
associated with HRQoL weights; each 10-bpm
increase in baseline heart rate was associated
with an HRQoL weights loss of approximately
0.02. The estimates have not been reported in
this paper; however, the HRQoL weights for
patients C70 bpm (n = 5313 patients) were
consequently only slightly higher than those
reported for patients in the subgroup with a
baseline heart rate C75 bpm (n = 3353
patients). Beta-blockade was not found to
predict differences in patients’ HRQoL once
these factors had been taken into account.
The mixed model predicted that HRQoL
weights scores for patients with a heart rate
C75 bpm ranged from 0.82 (NYHA I) to 0.46
(NYHA IV) for standard care patients and from
0.84 (NYHA I) to 0.47 (NYHA IV) for ivabradine
patients; ivabradine treatment itself was
associated with an HRQoL weight gain of 0.01.
The reduction in HRQoL weights score given a
hospitalization was found to be greater in those
patients in more severe NYHA classes [reduction
in HRQoL weights: 0.07–0.21 (NYHA I–IV)], see
Table 3. Whilst the treatment benefit of
ivabradine was not significantly modified by
baseline heart rate, there was some evidence of a
trend towards an effect (p = 0.13) (see Table 2).
In view of previous evidence of a treatment
interaction between ivabradine and baseline
Table 1 Baseline characteristics
Description Standard care
n5 2665 patients
Ivabradine
n5 2648 patients
Mean/freq SE/% Mean/freq SE/%
Treatment at randomization
Beta-blocker use
No beta-blockade 260 9.8% 260 9.8%
\half target dose 1060 39.8% 1062 40.1%
Chalf target dose,\target dose 715 26.8% 714 27.0%
Ctarget dose 630 23.6% 612 23.1%
ACE inhibitors 2110 79.2% 2121 80.1%
ARBs 355 13.3% 350 13.2%
Allopurinol 169 6.3% 162 6.1%
Loop diuretics 2096 78.7% 2109 79.7%
SE standard error, BMI body mass index, bpm beats per minute, LVEF left ventricular ejection fraction, HF heart failure,
MI myocardial infarction, ARBs angiotensin receptor blockers
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heart rate this interaction term was retained in
the final regression model used for the NICE
HTA submission (see Table 2) [4].
DISCUSSION
We have developed a mixed model using
longitudinal EQ-5D data from the SHIFT trial.
Whilst there are a number of approaches that
can be used to analyze HRQoL data, a mixed
model offered a number of advantages. In
particular, a mixed model enabled us to
explain variation in EQ-5D data by treatment
allocation, clinical outcomes (NYHA class and
hospitalization events), and patient baseline
characteristics, whilst taking into account the
longitudinal data structure. The mixed model
provided essential information for both short-
and long-term predictions of patient HRQoL
weights to populate a decision analytic
cost-effectiveness model. This method also
Table 2 Mixed model based on SHIFT patient-level data (with treatment interaction)
Description Coefficient SE p value 95% LCI 95% UCI
Treatment 0.0104 0.0047 0.0270 0.0012 0.0195
Age (years)a -0.0008 0.0002 0.0000 -0.0012 -0.0004
Female -0.0590 0.0057 0.0000 -0.0702 -0.0478
Hospitalization within 30 days -0.2116 0.0320 0.0000 -0.2744 -0.1489
NYHA II -0.0848 0.0089 0.0000 -0.1023 -0.0673
NYHA III -0.1798 0.0094 0.0000 -0.1982 -0.1614
NYHA IV -0.3656 0.0182 0.0000 -0.4012 -0.3300
Ischemia -0.0365 0.0054 0.0000 -0.0471 -0.0258
Stroke -0.0243 0.0086 0.0050 -0.0410 -0.0075
HF duration C0.6,\2 years -0.0191 0.0067 0.0040 -0.0322 -0.0061
HF duration C2,\4.8 years -0.0394 0.0068 0.0000 -0.0526 -0.0262
HF duration C4.8 years -0.0456 0.0068 0.0000 -0.0590 -0.0322
Allopurinol 0.0220 0.0098 0.0260 0.0027 0.0413
BMI kg/m2a -0.0026 0.0005 0.0000 -0.0035 -0.0016
Heart rate (bpm)a -0.0021 0.0004 0.0000 -0.0028 -0.0014
Loop diuretics dose/kg/day -0.0158 0.0032 0.0000 -0.0220 -0.0096
Potassium[5 mmol/L -0.0142 0.0060 0.0190 -0.0261 -0.0023
Hosp30 9 NYHA I 0.1403 0.0832 0.0920 -0.0228 0.3035
Hosp30 9 NYHA II 0.1792 0.0352 0.0000 0.1102 0.2482
Hosp30 9 NYHA III 0.1281 0.0344 0.0000 0.0607 0.1955
Treatment 9 heart rate 0.0008 0.0005 0.1330 -0.0002 0.0017
Cons 0.9082 0.0108 0.0000 0.8870 0.9293
LCI lower confidence interval, UCI upper confidence interval, NYHA New York Heart Association, HF heart failure, BMI
body mass index, SE standard error
a Variables centered on the mean
Adv Ther (2017) 34:753–764 761
allowed us to estimate the temporary loss in
HRQoL associated with hospitalizations. In
SHIFT many hospitalizations did not occur
close to EQ-5D data collection. Whilst
temporary changes in HRQoL associated with
all hospitalization events may not be captured
in the RCT data, such changes in HRQoL could
be predicted in our cost-effectiveness analysis
using estimates from the mixed model, based
on those events from which HRQoL weights
could be estimated. Ivabradine was associated
with a large reduction in hospitalizations in
SHIFT; hence, the ability to predict the HRQoL
weights loss associated with hospitalizations
represented an important feature of the
cost-effectiveness model.
It is noted that mixed models based on
longitudinal data commonly include a set of
time dummy variables to capture effects on the
dependent variable that may vary over time. In
our analysis a trend of increasing HRQoL was
evident over the observed trial period. When we
included time variables in the HRQoL
regression equation, the longer-term estimates
of HRQoL predicted from the HRQoL regression
equation exceeded values that might be
considered credible from a clinical perspective,
given that heart failure is a chronic and
progressive disease. In the cost-effectiveness
analysis, therefore, time variables were
excluded from the final HRQoL regression
equation.
It is further noted that whilst the mixed
model addresses many issues associated with
analyzing HRQoL data, it does not account for
the potential bias associated with missing data
which is not missing at random. Censoring of
HRQoL data may be ‘‘informative’’ since sicker
patients are expected to be less likely to provide
HRQoL responses. It is plausible that even in a
well-conducted trial such as SHIFT this could
distort final HRQoL weights estimates from the
mixed model.
The results from our analysis appear to
compare well with external data. Our results
indicate that HRQoL weights for patients
treated with ivabradine would range from 0.84
to 0.47, compared to 0.83–0.46 for standard care
alone (NYHA class I–IV, respectively). These
estimates are very similar to estimates of HRQoL
from a previous large study in HF patients and
appear to have good cross-validity (NYHA
classes I–IV 0.85–0.53 [17]; n = 1395).
CONCLUSION
Summary measures of HRQoL data are typically
inadequate for the needs of economic
evaluations and may fail to consider
limitations associated with a longitudinal
dataset. These limitations, if unaddressed, may
bias cost-effectiveness results, particularly given
the requirements to extrapolate parameter
estimates over the long term. In SHIFT a de
novo mixed model was employed to address
these limitations. Our analysis enabled us to
explain variation in EQ-5D data according to
key clinical outcomes and patient
characteristics, providing essential information
for predictions of patient HRQoL in the SHIFT
cost-effectiveness analysis. This method also
allowed us to estimate temporary losses in
HRQoL associated with hospitalizations. In
SHIFT many hospitalizations did not occur
close to EQ-5D data collection; hence,
temporary changes in HRQoL associated with
Table 3 Derived HRQoL weights values SHIFT average
patient (heart rate C75 bpm)
Health state HRQoL weights
Standard care (no hospitalization)
NYHA I 0.823
NYHA II 0.738
NYHA III 0.643
NYHA IV 0.457
HRQoL weights loss hospitalization
NYHA I -0.07
NYHA II -0.03
NYHA III -0.08
NYHA IV -0.21
Treatment effect ivabradine 0.014
NYHA New York Heart Association, bpm beats per
minute
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such events would not be captured in observed
RCT evidence, but could be predicted in our
cost-effectiveness analysis using the mixed
model. Given the large reduction in
hospitalizations associated with ivabradine this
is an important benefit for treated patients
which may otherwise have been overlooked.
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